Intelligence Profile
Science
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor. Its primary mechanism of action involves the blocking of the PDE5 enzyme, predominantly found in the smooth muscle of the corpus cavernosum, prostate, bladder, and vascular tissues. By inhibiting PDE5, tadalafil prevents the breakdown of cyclic guanosine monophosphate (cGMP).
Molecular Mechanism:
Nitric Oxide Release: Sexual stimulation leads to the release of nitric oxide (NO) in the corpus cavernosum.
cGMP Production: NO stimulates the enzyme guanylate cyclase, increasing the conversion of guanosine triphosphate (GTP) to cGMP.
Smooth Muscle Relaxation: Elevated cGMP levels cause relaxation of smooth muscle in the corpus cavernosum, allowing blood flow and facilitating erection.
PDE5 Inhibition: Tadalafil prolongs the action of cGMP by inhibiting its degradation by PDE5, maintaining vasodilation and erection.
Physiological Effects:
Beyond erectile dysfunction, tadalafil impacts other physiological systems:
BPH and LUTS: Tadalafil lowers symptoms of benign prostatic hyperplasia by improving blood flow and reducing prostate smooth muscle tension.
Endothelial Function: Studies indicate tadalafil may have effects on endothelial and angiogenic biomarkers, improving vascular health (Naunyn-Schmiedeberg's archives of pharmacology, 2026).
NO-sGC-cGMP Pathway in PH: Tadalafil’s potential benefits in pulmonary hypertension are linked to enhanced efficacy of the NO-sGC-cGMP pathway, improving pulmonary vasodilation (Pulmonary circulation, 2026).
It is important to consult healthcare providers for specific medical guidance. This information is for educational purposes and is not a substitute for professional medical advice.